日本薬理学会年会要旨集
Online ISSN : 2435-4953
第93回日本薬理学会年会
セッションID: 93_3-O-111
会議情報

一般演題(口頭)
がん幹細胞マーカーCD133を標的とした抗体創薬
*加藤 幸成金子 美華大石 智一川田 学
著者情報
会議録・要旨集 オープンアクセス

詳細
抄録

Background: Cancer stem cells contribute to tumorigenesis, metastasis, and chemoresistance. A pentaspan membrane glycoprotein CD133 has been used for the isolation of stem-like cells from several cancers.

Purpose: In this study, we aimed to develop sensitive and specific anti-CD133 mAbs, which exerts anti-tumor and anti-metastasis activities.

Methods: Cell-Based Immunization and Screening (CBIS) method was employed for the development of anti-CD133 mAbs. LN229/CD133 glioblastoma cells were immunized into mice, and FCM was used for the first screening. WB and IHC screenings were further performed. Human colon cancer cell lines were used for examining the anti-tumor and the anti-metastasis activities of anti-CD133 mAbs.

Results: We established a novel anti-CD133 mAb, CMab-43 (IgG2a, kappa), which demonstrated a sensitive and specific reaction against colon cancer cells in FCM, WB, and IHC analyses. CMab-43 showed cancer-specific staining patterns in colon cancer tissues. Furthermore, CMab-43 significantly reduced tumor development of colon cancer cell xenografts, and inhibited experimental metastasis of colon cancer cells.

Conclusion: CMab-43 is useful for many applications and exerts anti-tumor or anti-metastasis activities. CMab-43 could be advantageous for antibody therapy against CD133-expressing colon cancers.

著者関連情報
© 2020 本論文著者
前の記事 次の記事
feedback
Top